DCM
RCUS icon

DAFNA Capital Management’s Arcus Biosciences RCUS Stock Holding History

DAFNA Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.59M Buy
443,829
+12,500
+3% +$270K 2.18% 12
2025
Q4 		$10.3M Sell
431,329
-196,297
-31% -$4M 2.39% 11
2025
Q3 		$8.54M Hold
627,626
– – 2.11% 12
2025
Q2 		$5.11M Buy
627,626
+2,500
+0.4% +$21.4K 1.41% 19
2025
Q1 		$4.91M Buy
625,126
+370,909
+146% +$4.3M 1.39% 21
2024
Q4 		$3.79M Sell
254,217
-2,500
-1% -$40.8K 0.96% 27
2024
Q3 		$3.93M Buy
256,717
+3,500
+1% +$55.2K 0.93% 28
2024
Q2 		$3.86M Buy
253,217
+21,500
+9% +$347K 0.92% 31
2024
Q1 		$4.37M Sell
231,717
-1,000
-0.4% -$17.3K 1% 30
2023
Q4 		$4.44M Buy
232,717
+10,000
+4% +$160K 1.07% 31
2023
Q3 		$4M Sell
222,717
-3,000
-1% -$60.3K 1.24% 27
2023
Q2 		$4.58M Buy
225,717
+50,500
+29% +$962K 1.25% 26
2023
Q1 		$3.2M Buy
175,217
+33,000
+23% +$631K 0.96% 33
2022
Q4 		$2.94M Sell
142,217
-36,500
-20% -$1M 0.83% 36
2022
Q3 		$4.67M Sell
178,717
-9,000
-5% -$238K 1.26% 27
2022
Q2 		$4.76M Buy
187,717
+42,500
+29% +$1.04M 1.3% 24
2022
Q1 		$4.58M Buy
145,217
+28,017
+24% +$939K 1.19% 26
2021
Q4 		$4.74M Sell
117,200
-6,500
-5% -$252K 1.19% 23
2021
Q3 		$4.31M Buy
123,700
+4,000
+3% +$124K 1.14% 23
2021
Q2 		$3.29M Buy
119,700
+62,100
+108% +$1.77M 0.69% 37
2021
Q1 		$1.62M Buy
57,600
+8,000
+16% +$278K 0.38% 58
2020
Q4 		$1.29M Sell
49,600
-22,500
-31% -$545K 0.38% 55
2020
Q3 		$1.24M Hold
72,100
– – 0.4% 49
2020
Q2 		$1.78M Buy
72,100
+44,302
+159% +$1.2M 0.51% 42
2020
Q1 		$386K Buy
+27,798
New +$346K 0.16% 71
2018
Q2 		– Sell
-7,500
Closed -$116K – 80
2018
Q1 		$116K Buy
+7,500
New +$125K 0.06% 70

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

DAFNA Capital Management's RCUS Position: Q1 2026 in Review

DAFNA Capital Management increased its Arcus Biosciences (RCUS) stake by 2.9% in Q1 2026, buying an estimated $270K and bringing the position to 443,829 shares worth $9.59M. The position accounts for 2.18% of the portfolio, ranked #12.

DAFNA Capital Management first reported a position in RCUS in Q1 2018 and has held it in 26 quarters since. The position peaked at $10.3M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • DAFNA Capital Management held 443,829 shares of Arcus Biosciences worth $9.59M as of Q1 2026.
  • DAFNA Capital Management bought 12,500 Arcus Biosciences shares in Q1 2026, an estimated $270K.
  • Arcus Biosciences made up 2.18% of DAFNA Capital Management's portfolio in Q1 2026, its #12 holding.
  • DAFNA Capital Management first reported a position in Arcus Biosciences in Q1 2018 and has held it in 26 quarters since.
  • DAFNA Capital Management's Arcus Biosciences position peaked at $10.3M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.